← Back to Analyst Consensus 
ORIC Buy
Oric Pharmaceuticals, Inc.
Current Price —
Implied Upside —
Analysts 21
30-Day Momentum
▲ 1 upgrades / ▼ 0 downgrades / 1 reiterations from 2 firms
Next Earnings
Nov 9, 2026 (14 days)
Rating Timeline
| Date ▼ | Firm | Action | From → To Rating | Price Target | Firm Rating |
|---|---|---|---|---|---|
| Oct 14, 2026 | JP Morgan | maintain | Overweight → Overweight | — | 54% |
| Oct 5, 2026 | Leerink Partners | initiate | — → Outperform | — | 51% |
| Sep 23, 2026 | BTIG | initiate | — → Buy | — | 52% |
| Aug 10, 2026 | HC Wainwright & Co. | maintain | Buy → Buy | — | 44% |
| Jun 8, 2026 | HC Wainwright & Co. | reiterate | Buy → Buy | — | 44% |
| May 15, 2026 | Goldman Sachs | upgrade | — → Buy | — | 54% |
| May 5, 2026 | Citigroup | maintain | Buy → Buy | — | 54% |
| Apr 2, 2026 | HC Wainwright & Co. | reiterate | Buy → Buy | — | 44% |
| Apr 1, 2026 | Wedbush | maintain | Outperform → Outperform | — | 58% |
| Mar 13, 2026 | HC Wainwright & Co. | reiterate | Buy → Buy | — | 44% |
| Feb 24, 2026 | Citigroup | maintain | Buy → Buy | $17 | 54% |
| Feb 24, 2026 | HC Wainwright & Co. | maintain | Buy → Buy | $25 | 44% |
| Feb 24, 2026 | Wedbush | reiterate | Outperform → Outperform | $20 | 58% |
| Jan 13, 2026 | Wedbush | reiterate | Outperform → Outperform | $20 | 58% |
| Jan 7, 2026 | Piper Sandler | initiate | — → Overweight | $22 | 54% |
| Dec 8, 2025 | Wells Fargo | maintain | Overweight → Overweight | $25 | 54% |
| Dec 8, 2025 | Wedbush | reiterate | Outperform → Outperform | $20 | 58% |
| Nov 20, 2025 | Evercore ISI Group | initiate | — → Outperform | $25 | 58% |
| Nov 18, 2025 | Wolfe Research | initiate | — → Peer Perform | $0 | 53% |
| Nov 18, 2025 | JP Morgan | maintain | Overweight → Overweight | $20 | 54% |
| Nov 17, 2025 | Citigroup | maintain | Buy → Buy | $16 | 54% |
| Nov 14, 2025 | HC Wainwright & Co. | maintain | Buy → Buy | $23 | 44% |
| Nov 14, 2025 | Wells Fargo | maintain | Overweight → Overweight | $19 | 54% |
| Nov 14, 2025 | Oppenheimer | maintain | Outperform → Outperform | $15 | 52% |
| Aug 14, 2025 | JP Morgan | maintain | Overweight → Overweight | $17 | 54% |
| Aug 14, 2025 | HC Wainwright & Co. | maintain | Buy → Buy | $19 | 44% |
| Aug 13, 2025 | Guggenheim | reiterate | Buy → Buy | $18 | 52% |
| Jul 8, 2025 | Ladenburg Thalmann | initiate | — → Buy | $15 | 45% |
| May 19, 2025 | JP Morgan | maintain | Overweight → Overweight | $20 | 54% |
| May 9, 2025 | HC Wainwright & Co. | maintain | Buy → Buy | $22 | 44% |
| May 6, 2025 | Oppenheimer | maintain | Outperform → Outperform | $12 | 52% |
| May 6, 2025 | Cantor Fitzgerald | reiterate | Overweight → Overweight | $0 | 50% |
| May 5, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $21 | 44% |
| Feb 26, 2025 | Guggenheim | reiterate | Buy → Buy | $0 | 52% |
| Feb 26, 2025 | JP Morgan | maintain | Overweight → Overweight | $22 | 54% |
| Feb 26, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $21 | 44% |
| Feb 24, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $21 | 44% |
| Feb 21, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $21 | 44% |
| Feb 11, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $21 | 44% |
| Feb 10, 2025 | Guggenheim | maintain | Buy → Buy | $0 | 52% |
| Feb 6, 2025 | JP Morgan | maintain | Overweight → Overweight | $21 | 54% |
| Jan 14, 2025 | Cantor Fitzgerald | reiterate | Overweight → Overweight | $0 | 50% |
| Jan 13, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $21 | 44% |
| Nov 4, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $21 | 44% |
| Oct 31, 2024 | Wells Fargo | initiate | — → Overweight | $20 | 54% |
| Oct 31, 2024 | Jones Trading | initiate | — → Buy | $17 | 50% |
| Sep 23, 2024 | Cantor Fitzgerald | reiterate | — → Overweight | $0 | 50% |
| Sep 18, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $21 | 44% |
| Sep 10, 2024 | Wedbush | reiterate | Outperform → Outperform | $20 | 58% |
| Sep 9, 2024 | Cantor Fitzgerald | reiterate | — → Overweight | $0 | 50% |
Price Target Trend
May 4, 2026 Oct 26, 2026
EPS Estimates
+1q —
0q —
+1y —
0y —
Cross-Platform Signals
No cross-platform signals in the last 90 days